Intravitreal bevacizumab and augmented trabeculectomy for neovascular glaucoma in young diabetic patients

Eye

Volumn 23, Issue 4, 2009, Pages 979-981

  Cornish, K Spiteri ^a   Ramamurthi, S ^a   Saidkasimova, S ^a   Ramaesh, K ^a  

^a GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

Author keywords

Bevacizumab; Glaucoma; Mitomycin; Neovascular; Trabeculectomy

Indexed keywords

APRACLONIDINE; BEVACIZUMAB; BRIMONIDINE; LATANOPROST; MITOMYCIN C; TIMOLOL MALEATE;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DIABETIC RETINOPATHY; GONIOSCOPY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INTRAOCULAR PRESSURE; INTRAOCULAR PRESSURE ABNORMALITY; IRIS RUBEOSIS; LASER COAGULATION; NEOVASCULAR GLAUCOMA; RETINA NEOVASCULARIZATION; TRABECULECTOMY; TREATMENT RESPONSE; VITRECTOMY; WOUND HEALING;

ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; DIABETES MELLITUS, TYPE 1; FEMALE; GLAUCOMA, NEOVASCULAR; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; TRABECULECTOMY; TREATMENT OUTCOME; VISUAL ACUITY; YOUNG ADULT;

EID: 65349130683     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2008.113     Document Type: Article

References (17)

1. Sisto D, Vetrugno M, Trabucco T, Cantatore F, Ruggeri G, Sborgia C. The role of antimetabolites in filtration surgery for neovascular glaucoma: intermediate-term follow-up. Acta Ophthalmol Scand 2007; 85(3): 267-271.
2. Mietz H, Raschka B, Krieglstein GK. Risk factors for failures of trabeculectomies performed without antimetabolites. Br J Ophthalmol 1999; 83(7): 814-821.
3. Salim S, Scott I, Fekrat S. Diagnosis and treatment of neovascular glaucoma. EyeNet 2001; 5(7): 35-37.
4. Sturmer J, Broadway DC, Hitchings RA. Young patient trabeculectomy. Assessment of risk factors for failure. Ophthalmology 1993; 100(6): 928-939.
5. Kiuchi Y, Sugimoto R, Nakae K, Saito Y, Ito S. Trabeculectomy with mitomycin C for treatment of neovascular glaucoma in diabetic patients. Ophthalmologica 2006; 220(6): 383-388.
6. Nissen N, Polverini PJ, Koch AE. Vascular Endothelial Growth Factor mediates angiogenic activity during the proliferative phase of wound healing. Am J Pathol 1998; 152(6): 1445-1452.
7. Stadelmann W, Digenis A, Tobin G. Physiology and healing dynamics of chronic cutaneous wounds. Am J Surg 1998; 176(Supp 2A): 26S-38S.
8. Arevalo J, Wu L, Sanchez J, Maia M, Saravia M, Fernandez C et al. Intravitreal bevacizumab for proliferative diabetic retinopathy: 6-months follow-up. Eye 2007, advance online publication September 2007; doi:10.1038/sj.eye.6702980. http://www.nature.com/eye/journal/vaop/ncurrent/ pdf/6702980.pdf.
9. Kelkar AS, Kelkar SB, Kelkar JA, Nagpal M, Patil SP. The use of intravitreal bevacizumab in neovascular glaucoma: a case report. Bull Soc Belge Ophthalmol 2007; 303: 43-45.
10. Gheith ME, Siam GA, de Barros DS, Garg SJ, Moster MR. Role of intravitreal bevacizumab in neovascular glaucoma. J Ocul Pharmacol Ther 2007; 23(5): 487-491.
11. Afshari N. Research in cornea and external disease in refining current concept and branching out into new avenues of investigation. Rev Ophthalmol Online April 2006, vol. 5, Number 13. http://www.revophth.com/ index.asp?page1-943.htm.
12. Hurwitz H, Saini S. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. Semin Oncol 2006; 33(5 Suppl 10): S26-S34.
13. Scappaticci FA, Fehrenbacher L, Cartwright T. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005; 91: 173-180.
14. Ichhpujani P, Ramasubramanian A, Kaushik S, Pandav SS. Bevacizumab in glaucoma: a review. Can J Ophthalmol 2007; 42(6): 812-815.
15. Grisanti S, Biester S, Peters S, Tatar O, Ziemssen F, Bartz- Schmidt KU. Intracameral bevacizumab for iris rubeosis. Am J Ophthalmol 2006; 142(1): 158-160.
16. Iliev ME, Domig D, Wolf-Schnurrbursch U, Wolf S, Sarra GM. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol 2006; 142(6): 1054-1056.
17. Mason III JO, Nixon PA, White MF. Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 2006; 142(4): 685-688.